S Korea approves use of 1st homegrown Covid-19 vaccine from SK Bioscience

SKYCovione is the country's first homegrown vaccine to have successfully completed all three phases of its clinical trial

Coronavirus vaccine, Covid-19 vaccines
Representative image
IANS Seoul
1 min read Last Updated : Jun 29 2022 | 12:13 PM IST

South Korea on Wednesday approved the use of SKYCovione, the country's first homegrown COVID-19 vaccine developed by SK Bioscience Co., taking a major step toward achieving vaccine sovereignty in the fight against the pandemic.

The Ministry of Food and Drug Safety (MFDS) said it approved the use of SKYCovione, also known as GBP510, through consultations of the ministry's Final Inspection Committee, following an "item approval" recommendation by MFDS' Central Pharmaceutical Affairs Council on Monday, Yonhap news agency reported.

SKYCovione is the country's first homegrown vaccine to have successfully completed all three phases of its clinical trial. SK Bioscience conducted a phase-three clinical trial on some 4,000 adults in six countries -- Thailand, Vietnam, New Zealand, Ukraine, the Philippines and South Korea.

It is a recombinant-protein vaccine based on novel two-component nanoparticles that can maximize the immune effect. It was jointly developed with the Institute for Protein Design at the University of Washington.

The vaccine has been designed for recipients to receive two doses in a four-week interval.

--IANS

int/svn/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :South KoreaCoronavirus VaccineHealth Ministry

First Published: Jun 29 2022 | 12:13 PM IST

Next Story